Back to top

Analyst Blog

Yesterday, CME Group Inc. (CME - Analyst Report) unveiled new foreign exchange (FX) futures contracts in Indian Rupee (INR) on its Globex platform. This is an attempt to take an extra step of developing business into rapidly growing nations.

The new INR futures will begin trading from January 28, 2013 onwards, subject to regulatory approval. On the same day, arch-rival IntercontinentalExchange Inc. (ICE - Analyst Report) will begin trading its FX futures contracts in INR and Brazilian Real, as announced last month. Consequently, both the exchanges will become the first ones to offer futures contract in INR in the US.

Meanwhile, CME Group will launch INR FX futures in standard-sized and e-micro contract, which will be 20% of the value of the standard contract. The notional value of a standard-sized contract is pegged at INR5.0 million. Further, this non-deliverable forward currency will be settled in cash and will be hedged against the US dollar.

We believe that the accelerated demand for flexible and capital-efficient exchange tools in the emerging economies are paving way for diversified growth opportunities for the global exchange giants. Further, the addition of INR FX futures completes CME Group’s FX futures’ product suite, which now includes currencies from all the BRIC (Brazil, Russia, India and China) nations.

CME Group now leads the global derivative exchanges with comprehensive product portfolio of 56 futures and 31 options contracts, with an average daily notional value of US$110 billion in 2012. Additionally, the company offers over-the-counter (OTC) clearing services for 12 OTC non-deliverable forward currency pairs along with 26 cash-settled forward contracts.

Going ahead, CME Group continues to strategize its product and service offering to attain a strong foothold in the emerging markets. The company has achieved a competitive leverage by demonstrating immense growth potential in its futures and OTC market as well. The introduction of new products is also crucial for the company’s core growth, which has been following the ongoing weak industry trends.

Currently, the Zacks Consensus Estimate for the fourth quarter operating earnings is pegged at 64 cents per share, which would dip about 10% from the year-ago quarter. Over the last 30 days, 6 out of 14 analysts covering the stock have reduced their estimates for the fourth quarter of 2012, while one upward revision was witnessed. Subsequently, earnings estimate of $3.04 per share for 2012 exhibit a cautious outlook with an expected year-over-year negative growth of 11%.

The company carries a Zacks #4 Rank that implies a short-term Sell rating, while the long-term recommendation stands at Neutral.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UNITED THER… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%
STRATTEC SE… STRT 80.24 +3.00%